VACCINEX, INC. Quarterly Operating Income (Loss) in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Vaccinex, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q2 2024.
  • Vaccinex, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$5.72M, a 19.1% increase year-over-year.
  • Vaccinex, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$21.6M, a 1.62% increase year-over-year.
  • Vaccinex, Inc. annual Operating Income (Loss) for 2023 was -$22.9M, a 15% decline from 2022.
  • Vaccinex, Inc. annual Operating Income (Loss) for 2022 was -$19.9M, a 11.5% increase from 2021.
  • Vaccinex, Inc. annual Operating Income (Loss) for 2021 was -$22.5M, a 20.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$21.6M -$5.72M +$1.36M +19.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$23M -$5.07M -$88K -1.77% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$22.9M -$4.99M +$131K +2.56% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-04-25
Q3 2023 -$23M -$5.83M -$1.04M -21.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$22M -$7.08M -$1.68M -31% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$20.3M -$4.99M -$392K -8.53% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$19.9M -$5.12M +$399K +7.23% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-04-25
Q3 2022 -$20.3M -$4.79M +$271K +5.35% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$20.6M -$5.4M +$268K +4.73% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$20.8M -$4.59M +$1.65M +26.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$22.5M -$5.52M +$571K +9.38% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$23.1M -$5.06M +$3.52M +41% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$26.6M -$5.67M +$831K +12.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$27.4M -$6.24M +$919K +12.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$28.3M -$6.09M +$250K +3.94% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$28.6M -$8.58M -$905K -11.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$27.7M -$6.5M +$2.36M +26.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$30M -$7.16M +$1.98M +21.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$32M -$6.34M +$2.22M +26% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$34.2M -$7.68M -$1.22M -19% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$33M -$8.86M -$2.3M -35.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$30.7M -$9.14M -$3.43M -60.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$27.3M -$8.56M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$6.45M -$1.12M -21% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$6.56M -$1.89M -40.5% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$5.71M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2017 -$5.33M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$4.67M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.